Senseonics Holdings, Inc. Common Stock logo

SENSSenseonics Holdings, Inc. Common Stock

NASDAQ · Healthcare · Medical Devices

$9.38

+$0.15 (+1.63%)

Senseonics Holdings, Inc. Common Stock (SENS) is a medical devices company listed on NASDAQ. It is led by Timothy T. Goodnow Ph.D., based in 20451 Seneca Meadows Parkway, Germantown, MD, United States, 20876-7005, with about 130 employees. Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Latest reported SENS revenue for 2025-09-30 was $8.1M. Net income was -$48.3M. Revenue was up 21.7% from 2025-06-30 to 2025-09-30. SENS currently screens at market cap $377.4M.

Use this SENS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SENS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SENS SEC filings page. Lician reads the product cache first so this HTML stays unique to Senseonics Holdings, Inc. Common Stock even when a live quote feed is slow.

About Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

SENS Key Statistics

Market Cap

$377.43M

Volume

151,376

Previous Close

$9.38

Day Range

$9.31$9.74

0

P/B Ratio

10.99

EPS

-$0.12

Revenue

$22.47M

Net Income

-$78.62M

Gross Profit

$0.00

Free Cash Flow

$0.00

Revenue Growth

+0.4%

Profit Margin

-349.8%

Employees

130

SENS Financials

Annual income statement in USD. Latest reported periods first.

SENS annual income statement across FY2024, FY2023, FY2022
LineFY2024FY2023FY2022
Revenue$22.47M$22.39M$16.39M
Cost of Revenue$0.00$0.00$0.00
Gross Profit$0.00$0.00$0.00
Operating Income$0.00$0.00$0.00
Net Income-$78.62M-$60.39M$142.12M
EPS (Diluted)-$0.12-$0.11-$0.11

Total Assets

$100.44M

Total Debt

$0.00

Shareholders' Equity

$0.00

Cash & Equivalents

$74.60M

Operating Cash Flow

-$60.47M

Free Cash Flow

$0.00

Senseonics Holdings, Inc. Common Stock Company Information

President, CEO & Director
Timothy T. Goodnow Ph.D.
Headquarters
20451 Seneca Meadows Parkway, Germantown, MD, United States, 20876-7005
Phone
301 515 7260
IPO / Founded
2016-03-17
Industry
Medical Devices
Data Updated:

Upcoming Events for SENS